Previous studies demonstrate that both the genetic knockdown and pharmacological inhibition of STAT5A/B partially suppresses DNA repair, thereby augmenting radiotherapy efficacy in prostate cancer cell lines [27]. Here, STAT5A is linked to prostate carcinoma.